Ariza, Celedenio P.

HRN: 24-46-18  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/10/2024
CO-AMOXICLAV 625MG (TAB)
03/10/2024
03/17/2024
ORAL
625mg
TID
Cap MR
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Pneumonia    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: